UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-K

[x]  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
     ACT OF 1934

     For the fiscal year ended June 30, 2008

[ ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

     For the transition period from __________ to ____________

     Commission file number 0-51861

                                   EZJR, Inc.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)

             Nevada                                    20-0667864
    ------------------------                      ------------------------
    (State of incorporation)                      (I.R.S. Employer ID No.)

              3415 Ocatillo Mesa Way, North Las Vegas, NV  89031
              -----------------------------------------------------
               (Address of principal executive offices)(Zip Code)
         Issuer's telephone number, including area code: (702) 631-4251

    Securities registered pursuant to Section 12(b) of the Act: None
    Securities registered pursuant to Section 12(g) of the Act: Common Stock

Indicate by check mark if the registrant is a well-known seasoned issuer, as
defined in Rule 405 of the Securities Act. [ ] Yes [X] No

Indicate by check mark if the registrant is not required to file reports
pursuant to Section 13 or Section 15(d) of the Act. [ ] Yes [X] No

Indicate by checkmark whether the issuer (1) filed all reports required to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
past 12 months (or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing requirements for
the past 90 days.  Yes [X] No [ ]

Indicate by checkmark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to
this Form 10-K. [X]

Indicate by checkmark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See
the definitions of "large accelerated filer," "accelerated filer," and "smaller
reporting company" in Rule 12b-2 of the Exchange Act.

         [ ] Large accelerated filer      [ ] Accelerated filer
         [ ] Non-accelerated filer        [X] Smaller reporting company
         (Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act).
                                              Yes[ ] No [X]

State the aggregate market value of the voting and non-voting common equity
held by non-affiliates computed by reference to the price at which the common
equity was last sold, or the average bid and asked price of such common equity,
as of the last business day of the registrant's most recently completed second
fiscal quarter:

The Registrant's stock is not trading on any stock exchange.

Indicate the number of shares outstanding of each of the registrant's classes
of common stock, as of the latest practicable date:

As of September 24, 2008, there were 10,873,750 shares of the issuers Common
Stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE:

None.

Transitional Small Business Disclosure Format: Yes [ ] No [X]


<PAGE>


                                      INDEX


         Title                                                           Page

ITEM 1.  BUSINESS                                                          5

ITEM 2.  PROPERTIES                                                       21

ITEM 3.  LEGAL PROCEEDINGS                                                21

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS               21

ITEM 5.  MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER  MATTERS        22

ITEM 7.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF                          23
         FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA                      27

ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON                 28
         ACCOUNTING AND FINANCIAL DISCLOSURE

ITEM 9A. CONTROLS AND PROCEDURES                                          28

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE           31

ITEM 11. EXECUTIVE COMPENSATION                                           34

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS,                 36
         MANAGEMENT AND RELATED STOCKHOLDER MATTERS

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS                   37
         AND DIRECTOR INDEPENDENCE

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES                           38

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES                          39




                                        2
<PAGE>


                            FORWARD-LOOKING STATEMENTS

This document contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements other than
statements of historical fact are "forward-looking statements" for purposes
of federal and state securities laws, including, but not limited to, any
projections of earnings, revenue or other financial items; any statements of
the plans, strategies and objections of management for future operations; any
statements concerning proposed new services or developments; any statements
regarding future economic conditions or performance; any statements or
belief; and any statements of assumptions underlying any of the foregoing.

Forward-looking statements may include the words "may," "could," "estimate,"
"intend," "continue," "believe," "expect" or "anticipate" or other similar
words. These forward-looking statements present our estimates and assumptions
only as of the date of this report. Accordingly, readers are cautioned not to
place undue reliance on forward-looking statements, which speak only as of
the dates on which they are made. We do not undertake to update forward-
looking statements to reflect the impact of circumstances or events that
arise after the dates they are made.  You should, however, consult further
disclosures we make in future filings of our Annual Report on Form 10-K,
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Although we believe that the expectations reflected in any of our forward-
looking statements are reasonable, actual results could differ materially
from those projected or assumed in any of our forward-looking statements. Our
future financial condition and results of operations, as well as any forward-
looking statements, are subject to change and inherent risks and
uncertainties. The factors impacting these risks and uncertainties include,
but are not limited to:

o  inability to raise additional financing for working capital;

o  inability to locate new medical devices and integrate these products into
   our organization;

o  deterioration in general or regional economic, market and political
   conditions;

o  the fact that our accounting policies and methods are fundamental to how
   we report our financial condition and results of operations, and they may
   require management to make estimates about matters that are inherently
   uncertain;

o  adverse state or federal legislation or regulation that increases the costs
   of compliance, or adverse findings by a regulator with respect to existing
   operations;

o  changes in U.S. GAAP or in the legal, regulatory and legislative
   environments in the markets in which we operate;

                                        3
<PAGE>


o  inability to efficiently manage our operations;

o  inability to achieve future operating results;

o  our ability to recruit and hire key employees;

o  the inability of management to effectively implement our strategies and
   business plans; and

o  the other risks and uncertainties detailed in this report.

In this form 10-K references to "EZJR", "the Company", "we," "us," and "our"
refer to EZJR, Inc.

                              AVAILABLE INFORMATION

We file annual, quarterly and special reports and other information with the
SEC.  You can read these SEC filings and reports over the Internet at the
SEC's website at www.sec.gov.  You can also obtain copies of the documents at
prescribed rates by writing to the Public Reference Section of the SEC at 100
F Street, NE, Washington, DC 20549 on official business days between the
hours of 10:00 am and 3:00 pm.  Please call the SEC at (800) SEC-0330 for
further information on the operations of the public reference facilities.  We
will provide a copy of our annual report to security holders, including
audited financial statements, at no charge upon receipt to of a written
request to us at EZJR, Inc., 3415 Ocatillo Mesa Way, North Las Vegas,
NV  89031.

                                        4
<PAGE>


                                     PART I

ITEM 1.  BUSINESS

History and Organization
------------------------

EZJR, Inc., was organized by the filing of Articles of Incorporation
with the Secretary of State of the State of Nevada on December 30, 2005.

On July 25, 2008, EZJR, Inc. and IVPSA Corporation, ("IVP") a Nevada
corporation entered into to an Acquisition Agreement and Plan of Merger
(the "Merger Agreement") whereby IVP acquired all the outstanding shares of
common stock of EZJR from its sole stockholder in an exchange for $4,000 cash
in a transaction where IVP is the successor corporation.

Pursuant to Rule 12g-3(g) of the General Rules and Regulations of the
securities and Exchange Commission, IVP is the successor issuer to EZJR for
reporting purposes under the Securities Exchange Act of 1934, as amended (the
"Act").  The purpose of this transaction was for IVP to succeed to the
registration status of EZJR under the Exchange Act pursuant to Rule 12g-3.

EZJR, a reporting company was not engaged in any business.  It was
incorporated for the purpose of becoming a fully reporting company and
subsequently finding a merger candidate.  IVP's sole director and officer
became the sole director and officer of the surviving corporation.  The sole
director and officer of EZJR resigned.  Pursuant to the Acquisition Agreement
and Plan of Merger the Registrant did not change its corporate name following
the merger.  The name of the Registrant remains EZJR, Inc.  A copy of the
Merger Agreement and Certificate of Merger are incorporated by reference (See
Current Report on Form 8-K filed on July 28, 2008, with the U. S. Securities
and Exchange Commission.)

Our Business
------------

EZJR, Inc. is a developmental medical device company which plans to
produce medical devices, utilizing the services contract manufacturing
facilities.  EZJR does not have the resources to conduct any required
clinical trails to obtain FDA approval.  Therefore, EZJR plans to outsource
this task to third parties who have the facilities to conduct any required
clinical trials.  EZJR also plans to subcontract the manufacturing and
production process of any future medical device to a FDA approved contract
manufacturing facility which can produce sterile medical devices under Good
Manufacturing Practices.  The company plans to distribute its product(s) into
the marketplace through medical supply wholesalers, hospitals and health
maintenance organizations.



                                        5
<PAGE>


Exclusive Option Agreement
--------------------------

EZJR entered into an "Exclusive Option Agreement" with the Cleveland Clinic,
Cleveland, Ohio, on March 15, 2007 to investigate and conduct due diligence
with respect to the commercial viability of the licensable technology prior to
executing a formal License Agreement.  The technology consists of a central
line catheter with the ability to access the jugular bulb.  The jugular bulb
is part of the internal jugular vein that collects the blood from the brain,
from the superficial parts of the face, and from the neck.  This catheter was
invented by a physician at the Cleveland Clinic.  The Company paid the
Cleveland Clinic, a nonrefundable fee of $46,000 for this exclusive option
agreement.  The agreement terminates in March, 2009, or it can terminate upon
a material breach of either party, whereby the defaulting party has 30 days
to cure to avoid the breach.   Further, either party may terminate this
agreement at any time prior to the expiration of the option period, by
providing thirty (30) days written notice of same to the non-terminating
party.  Prior to the termination of this agreement, EZJR must either renew
this option agreement or enter into a licensing agreement with the Cleveland
Clinic.  Failure to do so, will result in a loss of this Exclusive Option
Agreement, and a loss of time, money, and resources expended on this project.


Central line catheter product
-----------------------------

Most patients in the neuro critical care setting as well as patients
undergoing neurovascular procedures receive a central line catheter.  Jugular
bulb oxygen saturation monitoring is a well established method used in
neurosurgical intensive care, particularly in context of head injury.
Jugular Bulb Saturation measures the efficiency of oxygen use by the brain.

Currently, catheters for measuring jugular venous oxygen saturation are
inserted into the jugular vein in a cephalad (toward the head) direction, with
an catheter accessing the jugular bulb.  The cephalad method is complex,
time-consuming and could lead to complications.  Traditionally,
anesthesiologists and critical care physicians use caudad (toward the feet)
catheter insertion to access the central venous system.  The fear of
complications with introducing a catheter towards the brain has discouraged
the clinicians in using this monitoring method.

A potential benefit that might be achieved after the development of this
catheter will provide anesthesiologists a method for double catheterization
(inserting both caudad and cephalad catheters) all within one catheter.  It
other words, this design provides for one catheter to monitor a patient's
vital signs, as compared to using two catheters for the same meansurements.

This proposed catheter will give access to the blood exiting the brain that
can which can help the anesthesiologist monitor brain metabolism and its
byproducts.  Such information is important to neuro-critical care units and
intracranial vascular surgical procedures.  This method has also been
suggested for monitoring the brain in cardiac surgical procedures.

                                        6
<PAGE>


Prototype Development
---------------------

EZJR's progress in the evaluation of this central line catheter is contingent
on developing a prototype.  This needs to be a working prototype that can be
readily duplicated by a contract manufacturer at a reasonable price.  In
November, 2007, EZJR signed a purchase order with Interplex Medical LLC of
Midford, OH, to help the Company develop this working prototype.  The terms
of the purchase order require that EZJR pays up to $25,000 for the
development of a prototype catheter.  Their engineers have begun the process
to build this prototype.  They are working closely with the physician
inventor from the Cleveland Clinic.  The major hurdle in this evaluation is
whether or not a working prototype can be built and can easily be replicated
with a contract manufacturer.  If a working prototype cannot be built, there
would be no reason to proceed in attempting to bring this medical device to
the market.


Existing or Probable Government Regulations
-------------------------------------------

An investigational device exemption ("IDE") allows the investigational device
to be used in a clinical study in order to collect safety and effectiveness
data required to support a Premarket Approval ("PMA") application or a
Premarket Notification submission to Food and Drug Administration ("FDA").
Clinical studies are most often conducted to support a PMA.  Investigational
use also includes clinical evaluation of certain modifications or new
intended uses of legally marketed devices.  All clinical evaluations of
investigational devices, unless exempt, must have an approved IDE before the
study is initiated.  Clinical evaluation of devices that have not been
cleared for marketing requires:

     o   an IDE approved by an institutional review board (IRB). If the study
         involves a significant risk device, the IDE must also be approved by
         FDA;

     o  informed consent from all patients;

     o  labeling for investigational use only

     o  monitoring of the study and;

     o  required records and reports.

In order to conduct a significant risk device study, EZJR must:

     o  submit a complete IDE application to FDA for review and obtain FDA
        approval of the IDE;

     o  submit the investigational plan and report of prior investigations
        and to the IRB at each institution where the investigation is to be
        conducted for review and approval; and

                                        7
<PAGE>


     o  select qualified investigators, provide them with all necessary
        information on the investigational plan and report of prior
        investigations, and obtain signed investigator agreements from them.

Once an IDE application is approved, the following requirements must be met
in order to conduct the investigation in compliance with the IDE regulation:

     o  Labeling - The device must be labeled in accordance with the labeling
        provisions of the IDE regulation and must bear the statement "CAUTION
        Investigational Device. Limited by Federal (or United States) law to
        investigational use."

     o  Distribution - Investigational devices can only be distributed to
        qualified investigators.

     o  Informed Consent - Each subject must be provided with and sign an
        informed consent form before being enrolled in the study.

     o  Monitoring - All investigations must be properly monitored to protect
        the human subjects and assure compliance with approved protocols.

     o  Commercialization, promotion, and misrepresentation of an
        investigational device and prolongation of the study are prohibited.

     o  Records and Reports - Sponsors and investigators are required to
        maintain specified records and make reports to investigators, IRBs,
        and FDA.


EZJR Funding Requirements
-------------------------

EZJR does not have the required capital or funding to complete this initial
project.  Management anticipates EZJR will require at least $500,000 to
complete to perform the required FDA studies and produce inventory.  The
Company has yet to source this funding.

Future funding could result in potentially dilutive issuances of equity
securities, the incurrence of debt, contingent liabilities and/or
amortization expenses related to goodwill and other intangible assets, which
could materially adversely affect the Company's business, results of
operations and financial condition.  Any future acquisitions of other
businesses, technologies, services or product(s) might require the Company to
obtain additional equity or debt financing, which might not be available on
terms favorable to the Company, or at all, and such financing, if available,
might be dilutive.

                                      8
<PAGE>


Competition
-----------

The medical device industry is highly competitive.  Factors contributing to
the industry's increasingly competitive market include regulatory changes,
product substitution, technological advances, and the entrance of new
competitors.

Most all of EZJR 's competitors have significantly greater financial,
marketing, other resources, and larger customer bases than EZJR has and are
more financially leveraged.  As a result, these competitors may be able to
adapt changes in customer requirements more quickly; introduce new and more
innovative products more quickly; better adapt to downturns in the economy or
other decreases in sales; better withstand pressure for cancelled services,
take advantage of acquisition and other opportunities more readily; devote
greater resources to the marketing and sale of their products; and adapt more
aggressive pricing policies.   All of which may contribute to intensifying
competition and may affect EZJR 's future revenue growth.

Patent, Trademark, License and Franchise Restrictions and Contractual
Obligations and Concessions

We currently have no pending or provisional patents or trademark
applications.


Research and Development Activities and Costs

The majority of EZJR expenses involved the costs related to the research and
development of the central line catheter.  These costs included entering into
two option contracts ($46,000), with the Cleveland Clinic, and paying for
catheter development costs (approximately $10,000).


Compliance With Environmental Laws

We are not aware of any environmental laws that have been enacted, nor are we
aware of any such laws being contemplated for the future, that impact issues
specific to our business. In our industry, environmental laws are anticipated
to apply directly to the owners and operators of companies. They do not apply
to companies or individuals providing consulting services, unless they have
been engaged to consult on environmental matters. We are not planning to
provide environmental consulting services.




                                        9
<PAGE>


Employees
---------

We have no full-time employees at the present time.  Our sole officer and
director, is responsible for all planning, developing and operational duties,
and will continue to do so throughout the early stages of our growth.

He plans to devote 5-10 hours per week of his time to EZJR's business.  All
functions including development, strategy, negotiations and clerical work is
being provided by the sole officer/director on a voluntary basis, without
compensation.

We have no intention of hiring employees until the business has been
successfully launched and we have sufficient, reliable revenue from our
operations.  Our officer and director is planning to do whatever work is
required until our business to the point of having positive cash flow.  We do
not expect to hire any employees during through 2008.

Item 1A. Risk Factors.


1. Since EZJR is a development stage medical device company, EZJR has
generated no revenues, and there are no assurances that its business plan
will be successful.

EZJR expects to incur operating losses in future periods as EZJR incurs
significant expenses associated with the initial startup of its business.
Further, there are no assurances that EZJR will be successful in realizing
revenues or in achieving or sustaining positive cash flow at any time in the
future.  Any such failure could result in the possible closure of EZJR's
business or force the Company to seek additional capital through loans or
additional sales of the Company's equity securities to continue business
operations, which would dilute the value of any shares owned by the Company's
shareholders.


2. If EZJR's business plan is not successful, EZJR may not be able to
continue operations as a going concern and its stockholders may lose their
entire investment in EZJR.

As discussed in the Notes to Financial Statements included in this Current
Report, at June 30, 2008, EZJR had no working capital.  EZJR had a net loss
of approximately $(57,691) from its inception to June 30, 2008.

These factors raise substantial doubt that EZJR will be able to continue
operations as a going concern, and EZJR's independent auditors included an
explanatory paragraph regarding this uncertainty in their report on the
financial statements for the period from inception to June 30, 2008.  EZJR's
ability to continue as a going concern is dependent upon generating cash flow
sufficient to fund operations and reducing operating expenses.  EZJR's
business plan may not be successful in addressing these issues.  If EZJR
cannot continue as a going concern, its stockholders may lose their entire
investment in EZJR.

                                        10
<PAGE>


3.  EZJR expects losses in the future because EZJR has no revenue.

EZJR has generated no revenues, management expects losses over the next
twelve (12) months since there are no revenues to offset the expenses
associated in executing EZJR's business plan.  EZJR cannot guarantee that it
will ever be successful in generating revenues in the future.  EZJR
recognizes that if the Company is unable to generate revenues, it will not be
able to earn profits or continue operations as a going concern.  There is no
history upon which to base any assumption as to the likelihood that the
Company will prove successful, and EZJR can provide selling shareholders with
no assurance that it will generate any operating revenues or ever achieve
profitable operations.


4. Since EZJR's officer does not devote his full time to the Company, his
other activities could slow down EZJR's operations.

T J Jesky, the sole officer of EZJR does not devote all of his time to the
Company's operations.  He is semi-retired and devotes his time to his family
and personal activities.   Therefore, it is possible that a conflict of
interest with regard to his time may arise based on his involvement in other
activities.  His other activities will prevent him from devoting full-time to
EZJR's operations which could slow EZJR's operations and may reduce its
financial results because of the slow down in operations.

The President and Director of the company, currently devotes approximately 5-
10 hours per week to company matters.  The responsibility of developing the
company's business, and fulfilling the reporting requirements of a public
company all fall upon Mr. Jesky.  Mr. Jesky was the former President of Eaton
Laboratories, the Company that spun off IVPSA Corporation.  EZJR has not
formulated a plan to resolve any possible conflict of interest with his other
business activities.  Mr. Jesky intends to limit his role in his other
activities and devote more of his time to EZJR after the Company attains a
sufficient level of revenue and is able to provide sufficient officers'
salaries per its business plan.  In the event he is unable to fulfill any
aspect of his duties to the company, EZJR may experience a shortfall or
complete lack of sales resulting in little or no profits and eventual closure
of the business.

5. EZJR's sole officer, Mr. T J Jesky, has no prior experience in running a
medical device company.

EZJR's sole executive officer has no experience in operating a medical
device company.  Mr. Jesky did serve as President of Eaton Laboratories from
February 2, 2000 (inception) until March 2007.  Due to his lack of experience
in running a medical device company, the executive officer may make wrong
decisions and choices regarding key decisions on behalf of the Company.
Consequently, EZJR may suffer irreparable harm due to management's lack of
experience in this industry.


                                      11
<PAGE>


6. If EZJR is unable to obtain additional funding, its business operations
will be harmed.  Even if EZJR does obtain additional financing its then
existing shareholders may suffer substantial dilution.

As of June 30, 2008, EZJR had no working cash nor equivalents.  EZJR needs at
least five hundred dollars ($500,000) in order to obtain FDA (Food and Drug
Administration) approval to market its potential medical device.  EZJR
determined that $500,000 is needed for:  1) engineering design and
specifications of the medical device; 2) production of the medical devise; 3)
FDA application process; 4) conducting the necessary FDA studies; and 5)
producing a working inventory of the medical device.

The company has yet to find sourcing for this endeavor.  The Company has
initial plans to develop a catheter medical device.  The regulatory
requirements of the FDA will be capital intensive, this project will also
require a larger working capital basis to maintain adequate inventories of
the approved product.  This need for additional funds will be derived from
future stock offerings.  These future offerings could significantly dilute
the value of any previous investor's investment.  If and when FDA approval
can be obtained for this product, the Company will be required to produce
product for distribution.  The company anticipates that its budge for
$500,000 will include retail inventory of the medical device.

There are no guarantees given that the Company will be able to find the
necessary financing or the necessary financing will be available, if required
or if available, will be on terms and conditions satisfactory to management.
The above outlined capital problems which could significantly affect the
value of any Common Shares and could result in the loss of an investor's
entire investment.

7. EZJR may not be able to raise sufficient capital or generate adequate
revenue to meet its obligations and fund its operating expenses.

Failure to raise adequate capital and generate adequate sales revenues to
meet EZJR's obligations and develop and sustain its operations could result
in reducing or ceasing EZJR's operations.  Additionally, even if EZJR does
raise sufficient capital and generate revenues to support its operating
expenses, there can be no assurances that the revenue will be sufficient to
enable EZJR to develop business to a level where it will generate profits and
cash flows from operations.  These matters raise substantial doubt about
EZJR's ability to continue as a going concern.  EZJR's independent auditors
currently included an explanatory paragraph in their report on the financial
statements regarding concerns about EZJR's ability to continue as a going
concern.



                                        12
<PAGE>


8. EZJR may not be able to compete with larger medical device companies, the
majority of whom have greater resources and experience than EZJR does.

The Company has no way of knowing that other companies may be working on
bringing the same medical device into the market.  In order to obtain FDA
approval to market a medical device, it can take almost a twelve (12) to
eighteen (18) months to obtain approval from the FDA.  And, there is no way
to know if someone else has submitted similar paperwork beforehand.
Therefore, there is always a possibility that similar medical device may
enter the market before EZJR's licensed product.

Many of the Company's competitors are significantly larger and have
substantially greater financial, distribution, marketing and other resources
and have achieved better recognition for their brand names for product lines
or certain products than the Company.  There is no assurance that the Company
will be able to compete successfully against present or future competitors or
that competitive pressures faced by the Company will not have a material
adverse effect on the Company.

9.  If EZJR receives regulatory approval EZJR will also be subject to ongoing
FDA obligation and continued regulatory review.

Any regulatory approvals that EZJR receives for its products may also be
subject to limitations on the indicated uses for which the product may be
marketed or contain requirements for potentially costly post-marketing
follow-up studies. In addition EZJR or its third party manufacturers may be
required to undergo a pre-approval inspection of manufacturing facilities by
the FDA and foreign authorities before obtaining marketing approval and will
be subject to periodic inspection by the FDA and corresponding foreign
regulatory authorities under reciprocal agreements with the FDA.  Such
inspections may result in compliance issues that could prevent or delay
marketing approval or require the expenditure of money or other resources to
correct noncompliance.

If a regulatory agency discovers previously unknown problems with a product,
such as adverse events of unanticipated severity or frequency, or problems
with the facility where the product is manufactured, a regulatory agency may
impose restrictions on that product, EZJR's collaborators, or EZJR, including
requiring withdrawal of the product from the market.  EZJR's product
candidates will also be subject to ongoing FDA requirements for the labeling,
packaging, storage, advertising, promotion, record-keeping, and submission of
safety and other post-market information on the drug.  If EZJR's product
candidates fail to comply with applicable regulatory requirements, a
regulatory agency may:

     o    issue warning letters;
     o    impose civil or criminal penalties;
     o    withdraw regulatory approval;
     o    suspend any ongoing clinical trials;
     o    refuse to approve pending applications or supplements to approved
          applications filed by EZJR or EZJR's collaborators;
     o    impose restrictions on operations, including costly new
          manufacturing requirements; or
     o    seize or detain products or require a product recall.

                                        13
<PAGE>


If EZJR fails to comply with applicable domestic regulatory requirements,
EZJR may be subject to fines, suspension or withdrawal of regulatory
approvals, product recalls, seizure of products, operating restrictions, and
criminal prosecution.

10.  EZJR faces the risk of not being able to comply with each of the steps
in the FDA pre-marketing approval process.

If EZJR is successful in raising the required funds to develop its first
medical device, there are no assurances that the Company can comply with the
required steps in the FDA pre-marketing approval process.  This includes
compiling studies accepted by FDA to their satisfaction.  Failure to do so,
would result in compiling new studies at an added expense to the Company.
The Company may not have the required funds to repeat FDA compliance studies.
This would mean EZJR would either need to seek more funding or close its
business operations.

11.  The FDA approval process can be very lengthy and uncertain

Upon the completion of the required testing, analysis of the testing, and
producing an actual manufacturing lot of the product, the Company will be
ready to submit an Application to the FDA for their review and comment.  EZJR
expects this process could take eleven months after EZJR obtains funding,
just to produce the required data for a Submission Application.  Once the
Application is received by the FDA, they have 180 days to respond to an
Application.  At that time, based on the data provide, they will most likely
comment on the Application in that they will require clarification or more
data.  The Company expects the FDA approval process to last between 10-12
months.  If the FDA requires additional data following the review of EZJR's
Application, this will require additional expense and loss of time to bring
its product to the market.  There exists an uncertainty on how long the
actual FDA approval process will taken, as they may require additional
information.  This uncertainty can adversely effect when EZJR can bring the
final product to the marketplace.















                                      14
<PAGE>


12.  To be successful, medical device(s) must be accepted by health care
professionals, who can be very slow to adopt or unreceptive to new
technologies and products.

EZJR's future medical devices, if approved for marketing, may not achieve
market acceptance since hospitals, physicians, patients or the medical
community in general may decide to not accept and utilize these products.
The product candidates that EZJR is attempting to develop represent
substantial departures from established treatment methods and will compete
with a number of more conventional drugs and therapies manufactured and
marketed by major medical device companies.  The degree of market acceptance
of any of our developed products will depend on a number of factors,
including:

     o    the establishment and demonstration to the medical community of the
          clinical efficacy and safety of EZJR's product candidates;

     o    the ability to create products that are superior to alternatives
          currently on the market, including in terms of pricing and
          cost-effectiveness, relative convenience, and ease of
          administration;

     o    the prevalence and severity of adverse side effects; and

     o    the ability to establish in the medical community the potential
          advantage of EZJR's medical device over alternative medical
          devices.

If the health care community does not accept EZJR's products for any of the
foregoing reasons, EZJR's revenues from the sale of any approved product
would be significantly reduced.

13.  If EZJR is unable to obtain and maintain patent and other intellectual
property ownership rights relating to the development medical devices, then
the Company may not be able to sell any medical devices, which would have a
material adverse impact on EZJR's results of operations and the price of the
Company's common stock.

EZJR currently does not own any right, title or interest in any patent
application for any medical device.  If in the future EZJR does file a patent
application, there are no assurances that it will not be successfully
challenged or circumvented by competitors or others.  EZJR has no assurance
that the United States Patent and Trademark Office will issue the Patent or
that the scope of any claims granted in an issued patent will provide broad
protection or a competitive advantage to us.  If the Patent fails to issue in
sufficient scope or at all, or if the patent issues but EZJR fails to
maintain and enforce EZJR's rights in the issued patent, or if EZJR fails to
maintain and protect its rights in other intellectual property, including
know-how, trade secrets and trademarks, such failures, individually and in
the aggregate, could have a material adverse effect upon EZJR's business
prospects, financial condition and results of operations.  If such patents
issue, they will be presumed valid, but there is no assurance that they will
not be successfully challenged or circumvented by competitors or others.

                                        15
<PAGE>


EZJR also relies upon trade secrets and other unpatented proprietary
technology.  No assurance can be given that the Company can meaningfully
protect its rights with regard to such unpatented proprietary technology or
that competitors will not duplicate or independently develop substantially
equivalent technology.


14.  The reimbursement status of newly approved healthcare products and
treatments is no established and failure to obtain adequate reimbursement
could limit EZJR's ability to market any products the Company may develop.

EZJR's ability to commercialize its product candidates in domestic markets
successfully will depend in part on the extent to which governmental
authorities, private health insurers, managed care programs, and other
organizations establish appropriate coverage and reimbursement levels for the
cost of EZJR's products and related treatments.  There is significant
uncertainty related to the reimbursement of newly approved medical devices.
Third party payors are increasingly attempting to contain healthcare costs
and challenging the prices charged for medical products and services, both by
limiting coverage and by reducing the level of reimbursement for medical
devices.  For example, the trend toward managed health care in the United
States, which could significantly influence the purchase of health care
services and products, as well as legislative proposals to reform health care
or reduce government insurance programs, may result in lower prices for the
product candidates or exclusion of any product candidates from coverage and
reimbursement programs.  If third parties fail to provide adequate
reimbursement for EZJR's products, consumers and health care providers may
choose not to use EZJR's products, which could significantly reduce EZJR's
revenues from the sale of any approved product and prevent EZJR from
realizing an acceptable return on the Company's investment in product
development.


15.  EZJR has no commercial production capability and EZJR may encounter
production problems or delays, which could result in lower revenues.

To date, EZJR has not produced any product.  To achieve anticipated customer
demand levels EZJR will need to find suppliers who can contract manufacturer
the products for the Company and provide the Company with adequate levels of
inventory.  EZJR's contract manufacturers may not be able to maintain
acceptable quality standards.  If EZJR cannot achieve the required level and
quality of production, the Company may need to outsource production or rely
on licensing and other arrangements with third parties.  EZJR may not be able
to successfully outsource its production or enter into licensing or other
arrangements under acceptable terms with these third parties, which could
adversely affect its business.  EZJR's inability to identify potential
manufacturers, or to enter into or maintain agreements with them on
acceptable terms, could delay or prevent the commercialization of its
products, which would adversely affect its ability to generate revenues and
could prevent the Company from achieving or maintaining profitability.  In
addition reliance on third-party manufacturers could reduce EZJR's gross
margins and expose the Company to the risks inherent in relying on others.
EZJR may also encounter problems with production yields, shortages of
qualified personnel, production costs, and the development of advanced
manufacturing techniques and process controls.

                                        16
<PAGE>

16.  EZJR will be required to comply with Good Manufacturing Requirements,
and its failure to do so may subject the Company to fines and other
penalties.

EZJR, or its other third party manufacturers of its products must comply with
current good manufacturing practice, or cGMP, requirements demanded by
customers and enforced by the FDA through its facilities inspection program.

These requirements include quality control, quality assurance, and the
maintenance of records and documentation.  EZJR, its collaborators, or other
third party manufacturers of EZJR's products may be unable to comply with
these cGMP requirements and with other FDA, state, and foreign regulatory
requirements.  These requirements may change over time and EZJR, or third
party manufacturers, may be unable to comply with the revised requirements.
A failure to comply with these requirements may result in fines and civil
penalties, suspension of production, suspension or delay in product approval,
product seizure or recall, or withdrawal of product approval. If the safety
of any quantities supplied by third-parties is compromised due to their
failure to adhere to applicable laws or for other reasons, EZJR may not be
able to obtain regulatory approval for, or successfully commercialize,
product candidates that the Company may develop.


17.  EZJR may incur substantial liabilities from any product liability
claims, including claims made against third parties EZJR has agreed to
indemnify.

EZJR faces an inherent risk of product liability exposure related to the
testing of its product candidates in human clinical trials, and will face an
even greater risk if the Company sells its product candidates commercially.
An individual may bring a liability claim against the Company if one of its
product candidates causes, or merely appears to have caused, an adverse
effect or injury.  These risks will exist even for products developed that
may be cleared for commercial sale.  If EZJR cannot successfully defend
itself against any product liability claims, EZJR may incur substantial
liabilities.  Regardless of merit or eventual outcome, liability claims may
result in any one or a combination of the following:

     o    injury to EZJR's reputation;

     o    withdrawal of clinical trial participants;

     o    costs of related litigation;

     o    substantial monetary awards to patients or other claimants;

     o    decreased demand for EZJR's product candidates;

     o    loss of revenues; and

     o    the inability to commercialize EZJR's product candidates.

                                        17
<PAGE>


EZJR intends to secure limited product liability insurance coverage, but the
Company may not be able to obtain such insurance on acceptable terms with
adequate coverage, or at reasonable or affordable costs.  The amount of
insurance coverage EZJR obtains may not be adequate to protect the Company
from all liabilities.  EZJR may not have sufficient resources to pay for any
liabilities resulting from a claim beyond the limit of, or excluded from, its
insurance coverage.


18.  EZJR's exclusive option agreement with the Cleveland Clinic is scheduled
to expire on April 14, 2009.

EZJR has entered into an exclusive option agreement with the Cleveland Clinic
to develop a medical device.  This option agreement is due to expire on April
14, 2009.  This option may be terminated by either party at any time prior to
the expiration of the option period, by providing thirty (30) days written
notice of same to the non-terminating party.  If EZJR is unable to renew this
agreement, the Company would have no rights to any technology to develop
products.  This option is not automatically renewable.  If at the termination
of this Agreement, the Cleveland Clinic does not allow EZJR to renew this
option agreement or covert this agreement into a licensing agreement, the
Company will lose its total investment and the time devoted to the
development of the catheter developed by a physician at the Cleveland Clinic.
This is a substantial risk to the Company.  Unless EZJR can identify a
replacement product(s), such as another medical device or another business
strategy, EZJR would need to close EZJR's business operations.

19. EZJR's sole officer/director and largest shareholder own a controlling
interest in EZJR's voting stock and selling shareholders will not have any
voice in the Company's management, which could result in decisions adverse to
EZJR's general shareholders.

EZJR's sole officer/director and its second largest stockholder, in the
aggregate, beneficially own approximately or have the right to vote
approximately 68.9% of EZJR's outstanding common stock.  As a result, these
two stockholders, acting together, will have the ability to control
substantially all matters submitted to EZJR's stockholders for approval
including:

a) election of EZJR's board of directors;

b) removal of any of EZJR's directors;

c) amendment of EZJR's Articles of Incorporation or bylaws; and

d) adoption of measures that could delay or prevent a change in control or
impede a merger, takeover or other business combination involving us.



                                        18
<PAGE>


As a result of their ownership and positions, these two individuals have the
ability to influence all matters requiring shareholder approval, including
the election of directors and approval of significant corporate transactions.
In addition, the future prospect of sales of significant amounts of shares
held by EZJR's director and executive officer could affect the market price
of its common stock if the marketplace does not orderly adjust to the
increase in shares in the market and the value of shareholder investment in
the company may decrease.  Management's stock ownership may discourage a
potential acquirer from making a tender offer or otherwise attempting to
obtain control of EZJR, which in turn could reduce the stock price or prevent
the stockholders from realizing a premium over the stock price.


                     RISKS RELATING TO EZJR'S COMMON SHARES
                     -------------------------------------

20.  EZJR may, in the future, issue additional common shares, which would
reduce selling shareholders' percent of ownership and may dilute EZJR's share
value.

The future issuance of common stock may result in substantial dilution in the
percentage of EZJR's common stock held by EZJR's then existing shareholders.
EZJR may value any common stock issued in the future on an arbitrary basis.
The issuance of common stock for future services or acquisitions or other
corporate actions may have the effect of diluting the value of the shares
held by EZJR's selling shareholders, and might have an adverse effect on any
trading market for EZJR's common stock.

21.  EZJR's common shares are subject to the "Penny Stock" Rules of the SEC
and the trading market in EZJR's securities is limited, which makes
transactions in EZJR's stock cumbersome and may reduce the value of an
investment in EZJR's stock.

The Securities and Exchange Commission has adopted Rule 15g-9 which
establishes the definition of a "penny stock," for the purposes relevant to
us, as any equity security that has a market price of less than $5.00 per
share or with an exercise price of less than $5.00 per share, subject to
certain exceptions.

For any transaction involving a penny stock, unless exempt, the rules
require: (a) that a broker or dealer approve a person's account for
transactions in penny stocks; and (b) the broker or dealer receive from the
investor a written agreement to the transaction, setting forth the identity
and quantity of the penny stock to be purchased.

In order to approve a person's account for transactions in penny stocks, the
broker or dealer must: (a) obtain financial information and investment
experience objectives of the person; and (b) make a reasonable determination
that the transactions in penny stocks are suitable for that person and the
person has sufficient knowledge and experience in financial matters to be
capable of evaluating the risks of transactions in penny stocks.

                                        19
<PAGE>


The broker or dealer must also deliver, prior to any transaction in a penny
stock, a disclosure schedule prescribed by the Commission relating to the
penny stock market, which, in highlight form: (a) sets forth the basis on
which the broker or dealer made the suitability determination; and (b) that
the broker or dealer received a signed, written agreement from the investor
prior to the transaction. Generally, brokers may be less willing to execute
transactions in securities subject to the "penny stock" rules.  This may make
it more difficult for selling shareholders to dispose of EZJR's Common shares
and cause a decline in the market value of EZJR's stock.

Disclosure also has to be made about the risks of investing in penny stocks
in both public offerings and in secondary trading and about the commissions
payable to both the broker-dealer and the registered representative, current
quotations for the securities and the rights and remedies available to an
investor in cases of fraud in penny stock transactions.  Finally, monthly
statements have to be sent disclosing recent price information for the penny
stock held in the account and information on the limited market in
penny stocks.


22. There is no current trading market for EZJR's securities and if a trading
market does not develop, purchasers of EZJR securities may have difficulty
selling their shares.

There is currently no established public trading market for EZJR's securities
and an active trading market in EZJR's securities may not develop or, if
developed, may not be sustained.


23.  Because EZJR does not intend to pay any cash dividends on its common
stock, the Company's stockholders will not be able to receive a return on
their shares unless they sell them.

EZJR intends to retain any future earnings to finance the development and
expansion of its business.  EZJR does not anticipate paying any cash
dividends on its common stock in the foreseeable future.  Unless EZJR pays
dividends, its stockholders will not be able to receive a return on their
shares unless they sell them.  There is no assurance that stockholders will
be able to sell shares when desired.












                                      20
<PAGE>


24. EZJR may issue shares of preferred stock in the future that may adversely
impact shareholder rights as holders of the Company's common stock.

EZJR's articles of incorporation authorize the Company to issue up to
5,000,000 shares of preferred stock.  Accordingly, the board of directors
will have the authority to fix and determine the relative rights and
preferences of preferred shares, as well as the authority to issue such
shares, without further stockholder approval.  As a result, the board of
directors could authorize the issuance of a series of preferred stock that
would grant to holders preferred rights to its assets upon liquidation, the
right to receive dividends before dividends are declared to holders of EZJR's
common stock, and the right to the redemption of such preferred shares,
together with a premium, prior to the redemption of the common stock.  To the
extent that EZJR does issue such additional shares of preferred stock, the
shareholders rights as holders of common stock could be impaired thereby,
including, without limitation, dilution of shareholder ownership interests in
EZJR.  In addition, shares of preferred stock could be issued with terms
calculated to delay or prevent a change in control or make removal of
management more difficult, which may not be in the best interest as holders
of common stock.


Item 1B. Unresolved Staff Comments.

Not applicable.

Item 2. Properties.

Our corporate headquarters are located at 3415 Ocatillo Mesa Way, North Las
Vegas, NV  89031.  We believe our current office space is adequate for our
immediate needs; however, as our operations expand, we may need to locate and
secure additional office space.

Item 3. Legal Proceedings.

From time to time, we may become involved in various lawsuits and legal
proceedings, which arise in the ordinary course of business.  However,
litigation is subject to inherent uncertainties, and an adverse result in
these or other matters may arise from time to time that may harm our
business.

We are not presently a party to any material litigation, nor to the knowledge
of management is any litigation threatened against us, which may materially
affect us.

Item 4. Submission of Matters to a Vote of Security Holders.

We did not submit any matters to a vote of our security holders during the past
fiscal year.



                                      21
<PAGE>


                                    PART II

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters
and Issuer Purchases of Equity Securities.

(a) Market Information

There is currently no established public trading market for EZJR, Inc.
securities.  A trading market in the Company's securities may never develop
or, if developed, it may not be able to be sustained.

(b) Holders of Common Stock

As of September 23, 2008, there were approximately 100 holders of record of
our Common Stock and 10,873,750 shares outstanding.

(c) Dividends

In the future we intend to follow a policy of retaining earnings, if any, to
finance the growth of the business and do not anticipate paying any cash
dividends in the foreseeable future.  The declaration and payment of future
dividends on the Common Stock will be the sole discretion of board of
directors and will depend on our profitability and financial condition,
capital requirements, statutory and contractual restrictions, future
prospects and other factors deemed relevant.


(d) Securities Authorized for Issuance under Equity Compensation Plans

There are no outstanding grants or rights or any equity compensation plan in
place.

Recent Sales of Unregistered Securities

IVPSA Corporation was a wholly-owned subsidiary of Eaton Laboratories.
The shares of IVPSA Corporation were issued to each of Eaton's shareholders
as a spin-off dividend of Eaton Laboratories, Inc.  There have been no
other issuances of stock.

Issuer Purchases of Equity Securities

We did not repurchase any of our equity securities during the years ended
June 30, 2008 or 2007.

Item 6. Selected Financial Data.

Not applicable.




                                        22
<PAGE>


Item 7. Management's Discussion and Analysis of Financial Condition and
Results of Operations.

Overview of Current Operations
------------------------------

EZJR, Inc., was organized by the filing of Articles of Incorporation
with the Secretary of State of the State of Nevada on December 30, 2005.

On July 25, 2008, EZJR, Inc. and IVPSA Corporation, a Nevada corporation
entered into to an Acquisition Agreement and Plan of Merger (the "Merger
Agreement") whereby IVP acquired all the outstanding shares of common stock
of EZJR from its sole stockholder in an exchange for $4,000 cash in a
transaction where IVP is the successor corporation.  The original founder's
shares for EZJR were cancelled upon the consummation of the Merger, and the
corporate name remained EZJR, Inc. following the Merger.

EZJR, Inc. is a developmental medical device company which plans to
produce medical devices, utilizing the services contract manufacturing
facilities.  EZJR does not have the resources to conduct any required
clinical trials to obtain FDA approval.  Therefore, EZJR plans to outsource
this task to third parties who have the facilities to conduct any required
clinical trials.  EZJR also plans to subcontract the manufacturing and
production process of any future medical device to a FDA approved contract
manufacturing facility which can produce sterile medical devices under Good
Manufacturing Practices.  The company plans to distribute its product(s) into
the marketplace through medical supply wholesalers, hospitals and health
maintenance organizations.

Exclusive Option Agreement
--------------------------

EZJR entered into an "Exclusive Option Agreement" with the Cleveland Clinic,
Cleveland, Ohio, on March 15, 2007 to investigate and conduct due diligence
with respect to the commercial viability of the licensable technology prior to
executing a formal License Agreement.  The technology consists of a central
line catheter with the ability to access the jugular bulb.  The jugular bulb
is part of the internal jugular vein that collects the blood from the brain,
from the superficial parts of the face, and from the neck.  This catheter was
invented by a physician at the Cleveland Clinic.  The Company paid the
Cleveland Clinic, a nonrefundable fee of $46,000 for this exclusive option
agreement.  The agreement terminates in March, 2009, or it can terminate upon
a material breach of either party, whereby the defaulting party has 30 days
to cure to avoid the breach.   Further, either party may terminate this
agreement at any time prior to the expiration of the option period, by
providing thirty (30) days written notice of same to the non-terminating
party.  Prior to the termination of this agreement, EZJR must either renew
this option agreement or enter into a licensing agreement with the Cleveland
Clinic.  Failure to do so, will result in a loss of this Exclusive Option
Agreement, and a loss of time, money, and resources expended on this project.

                                        23
<PAGE>


Results of Operations for the year ended June 30, 2008
------------------------------------------------------

We earned no revenues since our inception on August 14, 2006 through June 30,
2008.  We do not anticipate earning any significant revenues until such time
as we can bring to the market a medical device product.  We are presently in
the development stage of our business and we can provide no assurance that we
will be successful in developing any medical device products.

For the period inception through June 30, 2008, we generated no income.
Since our inception on August 14, 2006 we experienced a net loss of
$(57,691).  Our loss was attributed to organizational expenses and entering
into a exclusive option agreement for a medical device.  We anticipate our
operating expenses will increase as we enhance our operations.  The increase
will be attributed to professional fees to be incurred in connection with the
filing of a registration statement with the Securities Exchange Commission
under the Securities Act of 1933.  We anticipate our ongoing operating
expenses will also increase once we become a reporting company under the
Securities Exchange Act of 1934.

Revenues
--------

We generated no revenues for the period from August 14, 2006 (inception)
through June 30, 2008.  We do not anticipate generating any revenues for at
least 28 months.


Going Concern
-------------

Our independent auditors included an explanatory paragraph in their report on
the accompanying financial statements regarding concerns about our ability to
continue as a going concern.  Our financial statements contain additional
note disclosures describing the circumstances that lead to this disclosure by
our independent auditors.



                                      24
<PAGE>


Summary of any product research and development that we will perform for the
term of our plan of operation.
----------------------------------------------------------------------------

Our progress in product research and development is contingent upon
developing a central line catheter prototype.  This needs to be a working
prototype that can be readily duplicated by a contract manufacturer at a
reasonable price.  In November, 2007, EZJR signed a purchase order with
Interplex Medical LLC of Midford, OH, to help the Company develop this
working prototype.  The terms of the purchase order require that EZJR pays up
to $25,000 for the development of a prototype catheter.  Their engineers have
begun the process to build this prototype.  They are working closely with the
physician inventor from the Cleveland Clinic.  The major hurdle in this
evaluation is whether or not a working prototype can be built and can easily
be replicated with a contract manufacturer.  If a working prototype cannot be
built, there would be no reason to proceed in attempting to bring this
medical device to the market.

Expected purchase or sale of plant and significant equipment
------------------------------------------------------------

We do not anticipate the purchase or sale of any plant or significant
equipment; as such items are not required by us at this time.

Significant changes in the number of employees
----------------------------------------------

As of June 30, 2008, we did not have any employees.  We are dependent upon
our sole officer and a director for our future business development.  As our
operations expand we anticipate the need to hire additional employees,
consultants and professionals; however, the exact number is not quantifiable
at this time.

Liquidity and Capital Resources
-------------------------------

Our balance sheet as of June 30, 2008 reflects $7,500 assets and $8,257
liabilities.  Cash and cash equivalents from inception to date have been
sufficient to provide the operating capital necessary to operate to date.

Notwithstanding, we anticipate generating losses and therefore we may be
unable to continue operations in the future.  We anticipate we will require
additional capital up to approximately $500,000 and we would have to issue
debt or equity or enter into a strategic arrangement with a third party.  We
intend to try and raise capital through a private offering after this
registration statement is declared effective and our shares are quoted on the
Over the Counter Bulletin Board.  There can be no assurance that additional
capital will be available to us.  We currently have no agreements,
arrangements or understandings with any person to obtain funds through bank
loans, lines of credit or any other sources.


                                      25
<PAGE>


Our sole officer/director has agreed to donate funds to the operations of the
Company, in order to keep it fully reporting for the next twelve (12) months,
without seeking reimbursement for funds donated.

As a result of the Company's current limited available cash, no officer or
director received cash compensation during the year ended June 30, 2008. The
Company has no employment agreements in place with its officers.

Off-Balance Sheet Arrangements
------------------------------

We do not have any off-balance sheet arrangements that have or are reasonably
likely to have a current or future effect on our financial condition, changes
in financial condition, revenues or expenses, results or operations,
liquidity, capital expenditures or capital resources that is material to
investors.

Critical Accounting Policies and Estimates
------------------------------------------

Revenue Recognition:  We recognize revenue from product sales once all of the
following criteria for revenue recognition have been met: pervasive evidence
that an agreement exists; the services have been rendered; the fee is fixed
and determinable and not subject to refund or adjustment; and collection of
the amount due is reasonable assured.

New Accounting Standards
------------------------

In September 2006, the FASB issued Statement of Financial Accounting
Standards No. 157, Fair Value Measurements, ("SFAS 157"). SFAS 157 provides a
framework for measuring fair value when such measurements are used for
accounting purposes. The framework focuses on an exit price in the principal
(or, alternatively, the most advantageous) market accessible in an orderly
transaction between willing market participants. SFAS 157 establishes a
three-tiered fair value hierarchy with Level 1 representing quoted prices for
identical assets or liabilities in an active market and Level 3 representing
estimated values based on unobservable inputs. Under SFAS 157, related
disclosures are segregated for assets and liabilities measured at fair value
based on the level used within the hierarchy to determine their fair values.
We anticipate adopting SFAS 157 on its effective date of January 1, 2008 and
the financial impact, if any, upon adoption has not yet been determined.









                                      26
<PAGE>


In February 2007, the FASB issued Statement of Financial Accounting Standards
No. 159, The Fair Value Option for Financial Assets and Financial
Liabilities, including an amendment of FASB Statement No. 115, ("SFAS 159").
SFAS 159 permits fair value accounting to be irrevocably elected for certain
financial assets and liabilities on an individual contract basis at the time
of acquisition or at a remeasurement event date. Upon adoption of SFAS 159,
fair value accounting may also be elected for existing financial assets and
liabilities.  For those instruments for which fair value accounting is
elected, changes in fair value will be recognized in earnings and fees and
costs associated with origination or acquisition will be recognized as
incurred rather than deferred. SFAS 159 is effective January 1, 2008, with
early adoption permitted as of January 1, 2007.  We anticipate adopting SFAS
159 concurrent with the adoption of SFAS 157 on January 1, 2008, but have not
yet determined the financial impact, if any, upon adoption.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk.

Not applicable.

Item 8. Financial Statements and Supplementary Data.

Index to Financial Statements


                              Financial Statement
                              -------------------


<TABLE>
                                                                   PAGE
                                                                   ----
<S>                                                                <C>
Independent Auditors' Report                                       F-1
Balance Sheet                                                      F-2
Statements of Operations                                           F-3
Statements of Changes in Stockholders' Equity                      F-4
Statements of Cash Flows                                           F-5
Notes to Financials                                                F-6

</TABLE>



                                        27
<PAGE>


MOORE & ASSOCIATES, CHARTERED
  ACCOUNTANTS AND ADVISORS
  ------------------------
     PCAOB REGISTERED

           REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
           -------------------------------------------------------

To the Board of Directors
EZJR, Inc.
(A Development Stage Company)

We have audited the accompanying balance sheets of EZJR, Inc. (A
Development Stage Company) as of June 30, 2008 and 2007, and the related
statements of operations, stockholders' equity and cash flows for the years
then ended and from inception on August 14, 2006 through June 30, 2008.
These financial statements are the responsibility of the Company's
management.  Our responsibility is to express an opinion on these financial
statements based on our audits.

We conducted our audits in accordance with standards of the Public Company
Accounting Oversight Board (United States).  Those standards require that
we plan and perform the audits to obtain reasonable assurance about whether
the financial statements are free of material misstatement.  An audit
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements.  An audit also includes assessing
the accounting principles used and significant estimates made by management,
as well as evaluating the overall financial statement presentation.  We
believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of EZJR, Inc. (A
Development Stage Company) as of June 30, 2008 and 2007, and the related
statements of operations, stockholders' equity and cash flows for the years
then ended and from inception on August 14, 2006 through June 30, 2008, in
conformity with accounting principles generally accepted in the United
States of America.

The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern.  As discussed in Note 3 to the
financial statements, the Company is a development stage company with no
history of operations, limited assets, and has incurred operating losses
since inception. These factors raise substantial doubt about its ability to
continue as a going concern.  Management's plans concerning these matters
are also described in Note 3.  The financial statements do not include any
adjustments that might result from the outcome of this uncertainty.

/s/ Moore & Associates, Chartered
---------------------------------
    Moore & Associates Chartered
    Las Vegas, Nevada
    September 23, 2008

             2675 S. Jones Blvd. Suite 109, Las Vegas, NV 89146
                    (702) 253-7499 Fax (702) 253-7501

                                      F-1
<PAGE>


                                  EZJR, Inc.
                        (A Development Stage Company)
                                Balance Sheets

<TABLE>
<CAPTION>

Balance Sheets

                                              June 30,        June 30,
                                                2008            2007
                                              ----------    -------------
<S>                                           <C>           <C>
ASSETS

Current assets:
   Cash and equivalents                       $         -   $          -
   Prepaid expenses                                 7,500              -
                                              -----------   -------------
     Total current assets                           7,500              -
                                              ------------  -------------
TOTAL ASSETS                                  $     7,500   $          -
                                              ===========   =============

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:
   Accounts payable                                 8,257              -
                                              ------------  -------------
     Total liabilities                              8,257              -
                                              ------------  -------------

Stockholders' equity:
   Preferred stock, $0.001 par value,
     5,000,000 shares authorized,
     none issued                                        -              -
   Common stock, $0.001 par value, 70,000,000
    shares authorized, 10,873,750 shares and
     and 10,873,750 issued and outstanding
     as of 6/30/08 and 6/30/07 respectively        10,873         10,873
   Additional paid-in capital                      46,061         25,557
   (Deficit) accumulated during development
    stage                                         (57,691)       (36,430)
                                              ------------  -------------
     Total stockholders' equity                      (757)             -
                                              ------------  -------------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY    $         -   $          -
                                              ============  =============
</TABLE>

   The accompanying notes are an integral part of these financial statements.

                                      F-2
<PAGE>


                                 EZJR, Inc.
                       (A Development Stage Company)
                          Statements of Operations

<TABLE>
<CAPTION>

Statements of Operations
                                                        August 14,
                                  For the years            2006
                                 ended June 30,       (inception) to
                              ---------------------      June 30,
                                 2008       2007           2008
                            -----------  -----------   --------------
<S>                         <C>          <C>          <C>
Revenue                     $         -   $        -  $            -
                            -----------  -----------   --------------

Expenses:

General and administrative
 expenses                       18,761             -          18,761
Option Contract                  2,500        36,000          38,500
Incorporating Expenses                           430             430
                            -----------  -----------   --------------
   Total expenses               21,261        36,430          57,691
                            -----------  -----------   --------------

Net loss before income
 taxes                         (21,261)      (36,430)        (57,691)

Income tax expense                   -             -               -
                            -----------  ------------  --------------

Net income (loss)              (21,261)      (36,430)  $     (57,691)
                            ===========  ============  ==============

Net income (loss) per common
 share                      $    (0.00)  $   (0.00)
                            ===========  ==========

Weighted average number of
 common shares outstanding  10,873,750   10,873,750
                            ===========  ==========
</TABLE>


  The accompanying notes are an integral part of these financial statements.

                                      F-3
<PAGE>


                                 EZJR, Inc.
                       (A Development Stage Company)
                    Statements of Stockholders' Equity
    For the period August 14, 2006 (Date of Inception) to June 30, 2008



<TABLE>
<CAPTION>

Statements of Stockholders' Equity

                                                    (Deficit)
                                                   Accumulated
                          Common Stock   Additional  During        Total
                       ------------------ Paid-in   Development Stockholders'
                         Shares   Amount  Capital    Stage        Equity
                       ---------- ------- -------- ---------- --------------
<S>                    <C>        <C>      <C>      <C>        <C>
August 14, 2006
Contributed capital                        36,430                    36,430

August 14, 2006
stock issued as
a dividend from
Eaton Laboratories
at $0.001 per share     10,873,750  10,873 (10,873)                        -

Net income (loss) for
the year ended
June 30, 2007                                        (36,430)        (36,430)
                      ----------- ------- -------- ---------- ---------------
Balance,
June 30, 2007         10,873,750  10,873   25,557    (36,430)              -

April 2008
Contributed capital                        20,504                     20,504

Net income (loss) for
the year ended
June 30, 2008                                         (21,261)       (21,261)
                       ---------- ------- -------- ----------- --------------

Balance,
June 30, 2008          10,873,750 $10,873 $46,061  $  (57,691) $        (757)
                       ========== ======= ======== =========== ==============
</TABLE>

  The accompanying notes are an integral part of these financial statements.

                                      F-4
<PAGE>


                                EZJR, Inc.
                       (A Development Stage Company)
                          Statements of Cash Flows

<TABLE>
<CAPTION>

Statements of Cash Flows

                                                                August 14,
                                          For the years            2006
                                         ended June 30,        (inception) to
                                      ---------------------       June 30,
                                          2008       2007           2008
                                     -----------  -----------  --------------
<S>                                  <C>          <C>          <C>
Operating activities:
Net (loss)                           $  (21,261)     (36,430)  $     (57,691)
Adjustments to reconcile net loss
 to net cash provided (used) by
 operating activities:
   Increase in prepaid expenses          (7,500)           -          (7,500)
   Increase in accounts payable           8,257            -           8,257
                                     -----------  -----------  --------------
Net cash provided by operating
  activities                            (20,504)     (36,430)        (56,934)


Financing activities:
Contributed capital                      20,504       36,430          56,934
                                     -----------  -----------  --------------
Net cash provided by financing
  activities                             20,504       36,430          56,934

Net increase (decrease) in cash               -            -               -
Cash - beginning                              -            -               -
                                     -----------  -----------  --------------
Cash - ending                        $        -   $        -   $           -
                                     ===========  ===========  ==============

Supplemental disclosures:
   Interest paid                     $        -   $        -   $           -
                                     ===========  ===========  ==============
   Income taxes paid                 $        -   $        -   $           -
                                     ===========  ===========  ==============
   Non-cash transactions             $        -   $        -   $           -
                                     ===========  ===========  ==============
</TABLE>

  The accompanying notes are an integral part of these financial statements.

                                      F-5
<PAGE>



                                   EZJR, Inc.
                          (A Development Stage Company)
                          Notes to Financial Statements

NOTE 1.   General Organization and Business

The Company was organized August 14, 2006 (Date of Inception) under the laws
of the State of Nevada, as IVPSA Corporation.  The Company was incorporated
as a wholly owned subsidiary of Eaton Laboratories, Inc., a Nevada
corporation. Eaton Laboratories was incorporated February 2, 2002, and, at
the time of spin off was listed on the Over the Counter Bulletin Board.

The directors of Eaton Laboratories approved a spin off its IVPSA subsidiary
in the form of a stock dividend as of November 1, 2006 (the "Record Date").
The record shareholders of Eaton received one (1) unregistered common share,
par value $0.001, of IVPSA Corporation common stock for every share of Eaton
Laboratories common stock owned.  The IVPSA Corporation stock dividend was
based on 10,873,750 shares of Eaton common stock that were issued and
outstanding as of the record date.  Since IVPSA's business is related to
developing medical devices and Eaton's business was related to developing
generic pharmaceutical products, the Eaton directors decided it was in the
best interest of Eaton and IVPSA's shareholders to spin off IVPSA to minimize
any potential of conflict of interest, in accessing funding.

The spin-off transaction was accomplished by the distribution of certain
intellectual property, representing industry contacts, a third party
relationships and trade secrets.  It did not include the transfer of any hard
assets or liabilities.  This spin off was valued at par value since the
company holds no assets, is uncertain as to future benefit, the stock is not
trading, and the company has not even received a stock symbol.

Eaton retained no ownership in IVPSA Corporation following the spin off.
IVPSA Corporation is no longer a subsidiary of Eaton Laboratories.

The Company is a development stage enterprise in accordance with Statement of
Financial Accounting Standards ("SFAS") No. 7, "Accounting and Reporting by
Development Stage Enterprises".  The Company plans to develop and market
medical devices.

NOTE 2.    Summary of Significant Accounting Practices

The Company has no cash assets and liabilities of $8,257 as of June 30, 2008.
The relevant accounting policies are listed below.

Basis of Accounting
-------------------
The basis is United States generally accepted accounting principles.


                                      F-6
<PAGE>


                                 EZJR, Inc.
                         (A Development Stage Company)
                         Notes to Financial Statements


NOTE 2.    Summary of Significant Accounting Practices (Continued)

Earnings per Share
------------------
The basic earnings (loss) per share is calculated by dividing the Company's
net income (loss) available to common shareholders by the weighted average
number of common shares during the year.  The diluted earnings (loss) per
share is calculated by dividing the Company's net income (loss) available to
common shareholders by the diluted weighted  average number of shares
outstanding during the year.  The diluted weighted average number of shares
outstanding is the basic weighted number of shares adjusted as of the first
of the year for any potentially dilutive debt or equity.

The Company has not issued any options or warrants or similar securities
since inception.

Revenue recognition
-------------------
The Company recognizes revenue on an accrual basis as it invoices for
services.

Dividends
---------
The Company has not yet adopted any policy regarding payment of dividends.
No Dividends have been paid during the period shown.

Income Taxes
------------
The provision for income taxes is the total of the current taxes payable and
the net of the change in the deferred income taxes.  Provision is made for
the deferred income taxes where differences exist between the period in which
transactions affect current taxable income and the period in which they enter
into the determination of net income in the financial statements.

Year-end
--------
The Company originally selected December 31 as its year-end.  On March 31,
2008 the board of directors and majority of shareholders accepted a
change of the year-end to June 30.

Advertising
-----------
Advertising is expensed when incurred.  There has been no advertising
during the period.


                                      F-7
<PAGE>


                                   EZJR, Inc.
                         (A Development Stage Company)
                         Notes to Financial Statements

NOTE 2.    Summary of Significant Accounting Practices (Continued)

Use of Estimates
----------------
The preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and
liabilities at the date of the financial statements and the reported amounts
of revenue and expenses during the reporting period.  Actual results could
differ from those estimates.


NOTE 3 - Going concern

The accompanying financial statements have been prepared in conformity
with accounting principles generally accepted in the United States of
America, which contemplates continuation of the Company as a going concern.
As shown in the accompanying financial statements, the Company is a
development stage company with no history of operations, limited assets, and
has incurred operating losses since inception. These factors, among others,
raise substantial doubt about its ability to continue as a going concern.

The financial statements do not include any adjustments relating to the
recoverability of assets and classification of liabilities that might be
necessary should the Company be unable to continue as a going concern. The
Company's continuation as a going concern is dependent upon its ability to
obtain additional operating capital, commence operations, provide competitive
services, and ultimately to attain profitability. The Company intends to
acquire additional operating capital through equity offerings. There is no
assurance that the Company will be successful in raising additional funds.

NOTE 4 - Stockholders' equity

The Company is authorized to issue 70,000,000 shares of its $0.001 par value
common stock and 5,000,000 shares of its $0.001 par value preferred stock.

The Company was a subsidiary of Eaton Laboratories, Inc.  On November 1,
2006, the record shareholders of Eaton received a spin off dividend of one
(1) common share, par value $0.001, of IVPSA Corporation common stock for
every share of Eaton Laboratories common stock owned.

As of June 30, 2008, IVPSA Corporation has 10,873,750 of its common
stock issued and outstanding and none of its preferred stock issued nor
outstanding.

There have been no other issuances of common stock.


                                      F-8
<PAGE>


                                    EZJR, Inc.
                          (A Development Stage Company)
                          Notes to Financial Statements


NOTE 5.   Related Party Transactions

The Company does not lease or rent any property.  Office space is being
provided by the Company's director on a rent free basis.  The amount is not
considered material to the financial statements.  The Company believes that
its current facilities are adequate for its needs through the next twelve
months, and that, should it be needed, suitable additional space will be
available to accommodate expansion of the Company's operations on
commercially reasonable terms, although there can be no assurance in this
regard

The sole officer and director of the Company is involved in other business
activities and may, in the future, become involved in other business
opportunities.  If a specific business opportunity becomes available, such
persons may face a conflict in selecting between the Company and their other
business interests.  The Company has not formulated a policy for the
resolution of such conflicts.

The sole officer and director of the Company is not compensated for his
services.  The Company does not anticipate paying compensation to any
officer/director until the Company can generate a profit on a regular basis.
Further, the executive officer/director of the Company has no plans to take
any salary until the Company can generate a profit on a regular basis.
There are no Employment Agreements in place, and the sole officer/director
will not be compensated for services previously provided.  He will receive no
accrued remuneration.

The sole officer/director has donated funds to the operations of the Company,
in order to keep it fully reporting and operational for the next twelve (12)
months, without seeking reimbursement for funds donated.  Since inception on
August 14, 2006 through June 30, 2008, the officer/director of the Company
has donated $56,934 to the Company.


NOTE 6.    Provision for Income Taxes

The Company accounts for income taxes under Statement of Financial Accounting
Standards No. 109, "Accounting for Income Taxes" ("SFAS No. 109"), which
requires use of the liability method.  SFAS No. 109 provides that deferred
tax assets and liabilities are recorded based on the differences between the
tax bases of assets and liabilities and their carrying amounts for financial
reporting purposes, referred to as temporary differences.  Deferred tax
assets and liabilities at the end of each period are determined using the
currently enacted tax rates applied to taxable income in the periods in which
the deferred tax assets and liabilities are expected to be settled or
realized.


                                      F-9
<PAGE>


                                  EZJR, Inc.
                         (A Development Stage Company)
                         Notes to Financial Statements


NOTE 6.    Provision for Income Taxes  (Continued)

The provision for income taxes differs from the amount computed by applying
the statutory federal income tax rate to income before provision for income
taxes.  The sources and tax effects of the differences are as follows:


                   U.S federal statutory rate      (34.0%)
                   Valuation reserve                34.0%
                                                   ------
                   Total                               -%

NOTE 7.   Operating Leases and Other Commitments

The Company has no lease or other obligations.

NOTE 8.  Option Agreement

On March 30, 2007, the Company paid a nonrefundable fee of $36,000 to enter
into an Exclusive Option Agreement with the Cleveland Clinic, Cleveland, Ohio
for twelve (12) months to investigate and conduct due diligence with respect
to the commercial viability of a medical device prior to executing a formal
License Agreement.  This medical device consists of a central line catheter
with the ability to access the jugular bulb.  The Company shall be required
to remit royalty payments to the Cleveland Clinic on a quarterly basis based
on a percentage of net sales of this medical device subject to the license
agreement of not less than 7.5% nor more than 15%.  On April 10, 2008, the
Company paid a nonrefundable fee of $10,000 to extend the Exclusive Option
Agreement for one additional year.  These nonrefundable fees of $36,000 and
$10,000, respectively, were paid with donated funds from the Company by its
sole officer.


NOTE 9.   Recent Pronouncements

Statement No. 150

Accounting for Certain Financial Instruments with Characteristics of both
Liabilities and Equity

This Statement establishes standards for how a issuer classifies and measures
certain financial instrument with characteristics of both liabilities and
equity.



                                      F-10
<PAGE>


                                  EZJR, Inc.
                         (A Development Stage Company)
                         Notes to Financial Statements


Note 9.   Recent Pronouncements  (Continued)

Statement No. 151

Inventory Costs-an amendment of ARB No. 43, Chapter 4 (Issued 11/04)

This statement amends the guidance in ARB No. 43, Chapter 4. "Inventory
Pricing," to clarify the accounting for abnormal amounts of idle facility
expense, freight, handling costs, and wasted material (spoilage). Paragraph 5
of ARB 43, Chapter 4. previously stated that "...under some circumstances,
items such as idle facility expense, excessive spoilage, double freight and
re-handling costs may be so abnormal ass to require treatment as current
period charges...." This Statement requites that those items be recognized as
current-period charges regardless of whether they meet the criterion of "so
abnormal." In addition, this Statement requires that allocation of fixed
production overheads to the costs of conversion be based on the normal
capacity of the production facilities.

Statement No. 152

Accounting for Real Estate Time-Sharing Transactions - an amendment of FASB
States No. 66 and 67.

This Statement amends FASB Statement No. 66, Accounting fttr Sales oj'Real
Estate, to reference the financial accounting and reporting guidance for real
estate time-sharing transactions that is provided in AICPA Statement of
Position (SOP) 04-2, Accounting f.r Real Estate Tine-Sharing Transactions.
This Statement also amends FASB Statement No. 67, Accounting fttr Costs and
Initial Rental Operations of Real Estate Projects, to state that the guidance
for (a) incidental operations and (b) costs incurred to sell real estate
projects does not apply to real estate time-sharing transactions. The
accounting for those operations and costs is subject to the guidance in SOP
04-2.

Statement No. 153

Exchanges of Non-monetary Assets - an amendment of APB Opinion No. 29

The guidance in APB Opinion No. 29, Accounting for Non-monetary Transactions,
is based on the principle that exchanges of non-monetary assets should be
measured based on the fair value of the assets exchanged. The guidance in
that Opinion, however, included certain exceptions to the principle. This
Statement amends Opinion 29 to eliminate the exception for non-monetary
exchanges of similar productive assets and replaces it with a general
exception for exchanges of non-monetary assets that do not have commercial
substance. A non-monetary exchange has commercial substance if the

                                    F-11
<PAGE>


                                  EZJR, Inc.
                         (A Development Stage Company)
                         Notes to Financial Statements


Note 9.   Recent Pronouncements  (Continued)

SFAS NO. 154 Accounting Changes and Correction of Errors,

Supercedes APB No. 20, This statement requires that changes in accounting
principles be applied retrospectively for all prior periods shown, including
interim periods. The effective date is for fiscal years beginning after
December 15, 2005.

SFAS NO. 155 Accounting for Certain Hybrid Financial Instruments-an amendment
of FASB Statements No. 133 and 140

This statement amends FASB Statements No. 140, Accounting for Transfers and
Servicing of Financial Assets and Extinguishments of Liabilities. This
statement resolves issues addressed in Statement 133 Implementation Issue No.
D1, Application of Statement 133 to Beneficial Interests in Securitized
Financial Assets.  This statement is effective for all financial instruments
acquired or issued after the beginning of an entity's first fiscal year that
begins after September 15, 2006.

SFAS NO. 156 Accounting for Servicing of Financial Assets-an amendment of
FASB Statement No. 140

This statement amends FASB Statement No. 140 with respect to the accounting
for separately recognized servicing liabilities. An entity should adopt this
statement as of the beginning, of its first fiscal year that begins after
September 15, 2006.

SFAS NO. 157 Fair Value Measurements

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements,
which defines fair value, establishes a framework for measuring fair value in
generally accepted accounting principles, and expands disclosures about fair
value measurements. SFAS No. 157 does not require any new fair value
measurements, but provides guidance on how to measure fair value by
providing, a fair value hierarchy used to classify the source of the
information. This statement is effective for us beginning May 1, 2008.

SFAS NO. 158 Employers' Accounting for Defined Benefit Pension and Other
Postretirement Plans-an amendment of FASB Statements No. 87, 88, 106, and
132(R))


                                      F-12
<PAGE>


                                  EZJR, Inc.
                         (A Development Stage Company)
                         Notes to Financial Statements


Note 9.   Recent Pronouncements  (Continued)


This statement improves the financial reporting by requiring an employer to
recognize the overfunded or underfunded status of a defined benefit
postretirement plan (other than a multiemployer plan) as an asset or
liabilities in its statement of financial positions and to recognize changes
in that funded status in the year in which the changes occur through
comprehensive income of a business entity. This statement also improves
financial reporting by requiring an employer to measure the funded status of
a plan as of the date of its year-end statement of financial position, with
limited exceptions.

SFAS NO. 159 The Fair Value Option for Financial Assets and Financial
Liabilities-Including an amendment of FAS B Statement No. 115

This statement permits entities to choose to measure many financial
instruments and certain items at fair value. The objective is to improve the
financial reporting by providing entities with

the opportunity to mitigate volatility in reported earnings caused by
measuring related assets and liabilities differently without having to apply
complex hedge accounting provisions. This statement is expected to expand the
use of fair value measurement objectives for accounting for financial
instruments. This statement is effective as of the beginning of an entity's
first fiscal year that begins after November 15, 2007.

SFAS No. 160 Non-controlling Interest in Consolidated Financial Statements-an
amendment of ARB No.51

This statement amends ARB 51 to establish accounting and reporting standards
for the non-controlling interest in a subsidiary and for the deconsolidation
of a subsidiary. It also changes the way the consolidated income statement is
presented for non-controlling interest. This statement improves comparability
by eliminating diversity of methods. This statement also requires expanded
disclosure.

SFAS No. 161 This statement is intended to enhance the disclosure
requirements for derivative instruments and hedging activities as required by
SFAS 133.

SFAS 162 This statement indentifies the sources of accounting principles and
the framework for-selecting the principles to by used in the preparation of
financial statements for entities that are presented in conformity with
generally accepted accounting principles in the United States, (the GAAP
hierarchy).

                                      F-13
<PAGE>


                                  EZJR, Inc.
                         (A Development Stage Company)
                         Notes to Financial Statements

Note 9.   Recent Pronouncements  (Continued)
FIN No. 48

In June 2006, the FASB issued Interpretation No. 48 ("FIN No. 48"),
Accounting for Uncertainty in Income Taxes-an interpretation of FASB
Statement No. 109. which clarifies the accounting for uncertainty in income
taxes recognized in an enterprise's financial statements in accordance with
SFAS No. 109, Accounting.tor Income Taxes. The Interpretation provides a
recognition threshold and measurement attribute for the financial statement
recognition and measurement of a tax position taken or expected to be taken
in a tax return. Under FIN No. 48, the Company may recognize the tax benefit
from an uncertain tax position only if it is more likely than not that the
tax position will be sustained on examination by the taxing authorities,
based on the technical merits of the position. The tax benefits recognized in
the financial statements from such a position should be measured based on the
largest benefit that has a greater than 50% likelihood of being realized upon
ultimate settlement. FIN No. 48 also provides guidance on de-recognition,
classification, interest and penalties, accounting in interim periods,
disclosure, and transition. FIN No. 48 is effective for us beginning July 1,
2007.

In June 2006. the FASB ratified the Emerging Issues Task Force ("EITF")
consensus on EITF Issue No. 06-2, "Accounting for Sabbatical Leave and Other
Similar Benefits Pursuant to FASB Statement No. 43." EITF Issue No. 06-2
requires companies to accrue the costs of compensated absences under a
sabbatical or similar benefit arrangement over the requisite service period.
EITF Issue No. 06-2 is effective for us beginning July 1, 2007. The
cumulative effect of the application of this consensus on prior period
results should be recognized through a cumulative-effect adjustment to
retained earnings as of the beginning of the year of adoption. Elective
retrospective application is also permitted.

Staff Accounting Bulletin ("SAB") No. 108, Considering the Effects of Prior
Year Misstatements when Quantifying Current Year Misstatements. SAB No. 108
requires companies to quantify misstatements using both a balance sheet (iron
curtain) and an income statement (rollover) approach to evaluate whether
either approach results in an error that is material in light of relevant
quantitative and qualitative factors, and provides for a one-time cumulative
effect transition adjustment. SAB No. 108.

The FAS B has replaced SFAS No. 141 with a new statement on Business
Combinations that changes the way that minority interest is recorded and
modified as a parent's interest in a subsidiary changes.

Note 10  -  Subsequent Event
----------------------------

On July 25, 2008, EZJR, Inc. and IVPSA Corporation, a Nevada corporation
entered into an Acquisition Agreement and Plan of Merger whereby IVPSA
acquired all the outstanding shares of common stock of EZJR from its sole
stockholder in an exchange for $4,000 cash in a transaction where IVPSA
Corporation was the successor corporation.  The original EZJR stock was
cancelled.  Pursuant to the Merger Agreement, the Company's name remained
unchanged as EZJR, Inc.

                                      F-14
<PAGE>

Item 9. Changes in and Disagreements With Accountants On Accounting and
Financial Disclosure.

None.

Item 9A(T). Controls and Procedures.

Evaluation of disclosure controls and procedures
------------------------------------------------

Management is responsible for establishing and maintaining adequate internal
control over financial reporting and for the assessment of the effectiveness
of those internal controls.  As defined by the SEC, internal control over
financial reporting is a process designed by our principal executive
officer/principal financial officer, who is also the sole member of our Board
of Directors, to provide reasonable assurance regarding the reliability of
financial reporting and the reparation of the financial statements in
accordance with U. S. generally accepted accounting principles.

As of the end of the period covered by this report, we initially carried out
an evaluation, under the supervision and with the participation of our chief
executive officer (who is also our principal financial and accounting
officer), of the effectiveness of the design and operation of our disclosure
controls and procedures.  Based on this evaluation, our chief executive
officer and chief financial officer initially concluded that our disclosure
controls and procedures were not effective.


Management's Report On Internal Control Over Financial Reporting
----------------------------------------------------------------

Our management is responsible for establishing and maintaining adequate
internal control over financial reporting.  Internal control over financial
reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the
Securities Exchange Act of 1934 as a process designed by, or under the
supervision of, the company's principal executive and principal financial
officers and effected by the company's board of directors, management and
other personnel, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external
purposes in accordance with accounting principles generally accepted in the
United States of America and includes those policies and procedures that:

-  Pertain to the maintenance of records that in reasonable detail accurately
   and fairly reflect the transactions and dispositions of the assets of the
   company;


                                      28
<PAGE>


-  Provide reasonable assurance that transactions are recorded as necessary to
   permit preparation of financial statements in accordance with accounting
   principles generally accepted in the United States of America and that
   receipts and expenditures of the company are being made only in accordance
   with authorizations of management and directors of the company; and

-  Provide reasonable assurance regarding prevention or timely detection of
   unauthorized acquisition, use or disposition of the company's assets that
   could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements.  Projections of any
evaluation of effectiveness to future periods are subject to the risk that
controls may become inadequate because of changes in conditions, or that the
degree of compliance with the policies or procedures may deteriorate.  All
internal control systems, no matter how well designed, have inherent
limitations.  Therefore, even those systems determined to be effective can
provide only reasonable assurance with respect to financial statement
preparation and presentation.  Because of the inherent limitations of
internal control, there is a risk that material misstatements may not be
prevented or detected on a timely basis by internal control over financial
reporting. However, these inherent limitations are known features of the
financial reporting process.  Therefore, it is possible to design into the
process safeguards to reduce, though not eliminate, this risk.

As of June 30, 2008 management assessed the effectiveness of our internal
control over financial reporting based on the criteria for effective internal
control over financial reporting established in Internal Control--Integrated
Framework issued by the Committee of Sponsoring Organizations of the Treadway
Commission ("COSO") and SEC guidance on conducting such assessments.  Based
on that evaluation, they concluded that, during the period covered by this
report, such internal controls and procedures were not effective to detect
the inappropriate application of US GAAP rules as more fully described below.
This was due to deficiencies that existed in the design or operation of our
internal controls over financial reporting that adversely affected our
internal controls and that may be considered to be material weaknesses.

The matters involving internal controls and procedures that our management
considered to be material weaknesses under the standards of the Public
Company Accounting Oversight Board were: (1) lack of a functioning audit
committee due to a lack of a majority of independent members and a lack of a
majority of outside directors on our board of directors, resulting in
ineffective oversight in the establishment and monitoring of required
internal controls and procedures; (2) inadequate segregation of duties
consistent with control objectives; and (3) ineffective controls over period
end financial disclosure and reporting processes.  The aforementioned
material weaknesses were identified by our Chief Executive Officer in
connection with the review of our financial statements as of June 30, 2008.


                                        29
<PAGE>


Management believes that the material weaknesses set forth in items (2) and
(3) above did not have an effect on our financial results.  However,
management believes that the lack of a functioning audit committee and the
lack of a majority of outside directors on our board of directors results in
ineffective oversight in the establishment and monitoring of required
internal controls and procedures, which could result in a material
misstatement in our financial statements in future periods.

This annual report does not include an attestation report of the
Corporation's registered public accounting firm regarding internal control
over financial reporting.  Management's report was not subject to attestation
by the Corporation's registered public accounting firm pursuant to temporary
rules of the SEC that permit the Corporation to provide only the management's
report in this annual report.


Management's Remediation Initiatives
------------------------------------

In an effort to remediate the identified material weaknesses and other
deficiencies and enhance our internal controls, we have initiated, or plan to
initiate, the following series of measures:

We will create a position to segregate duties consistent with control
objectives and will increase our personnel resources and technical accounting
expertise within the accounting function when funds are available to us.
And, we plan to appoint one or more outside directors to our board of
directors who shall be appointed to an audit committee resulting in a fully
functioning audit committee who will undertake the oversight in the
establishment and monitoring of required internal controls and procedures
such as reviewing and approving estimates and assumptions made by management
when funds are available to us.

Management believes that the appointment of one or more outside directors,
who shall be appointed to a fully functioning audit committee, will remedy
the lack of a functioning audit committee and a lack of a majority of outside
directors on our Board.

We anticipate that these initiatives will be at least partially, if not
fully, implemented by June 30, 2009.  Additionally, we plan to test our
updated controls and remediate our deficiencies by June 30, 2009.

Changes in internal controls over financial reporting
-----------------------------------------------------

There was no change in our internal controls over financial reporting that
occurred during the period covered by this report, that has materially
affected, or is reasonably likely to materially affect, our internal controls
over financial reporting.


Item 9B. Other Information.

None.

                                        30
<PAGE>


                                    PART III

Item 10. Directors, Executive Officers and Corporate Governance.

The following table sets forth certain information regarding our current
directors and executive officers.  Our executive officers serve one-year
terms.


Name                         Age   Positions and Offices Held
---------------              ---   --------------------------
T J Jesky                    61    President, Secretary and Director


The Company is managed by T J Jesky, who has 22-years experience in the
pharmaceutical industry.  He is a former Division Manager for Procter &
Gamble Pharmaceuticals.  He began his pharmaceutical career in 1973 with
Norwich Pharmacal, whose headquarters were based in Norwich, New York.  This
company subsequently changed its name to Norwich Eaton, and in 1981 it was
purchased by Procter & Gamble.  Norwich Eaton subsequently changed its name
to Procter & Gamble Pharmaceuticals.  Mr. Jesky held various positions in the
company, including but not limited to:  District Manager, Key Account
Manager, Hospital Manager, Region Manager, Division Manager for U.S., Canada
and Puerto Rico.  He resigned from Procter & Gamble in 1995.  He became
President, CEO and sole stockholder of Studebaker's, Inc. a
restaurant/nightclub and real estate holding company in Arizona.  He
privately sold this business in 1997.  In 1997 through 1998, he owned and
operated a restaurant consulting business, named Ionosphere, Inc.  In 1998,
he resigned from the Company when it was acquired by Axonyx, Inc., which is
currently trading on the NASDAQ National Market, under the name TorreyPines
Therapeutics, Inc.  From 1996 through 1999 he was President and Chairman of
the Board of Boppers Holdings, Inc., a Nevada Corporation real estate
business; he resigned from the Company when it was acquired by e-Smart
Technologies, Inc. which is currently listed on the Pink Sheets.  In August,
1998, Mr. Jesky founded Barrington Laboratories, Inc., he resigned from the
Company when it was acquired by ModernGroove Entertainment, in January, 2001
and subsequently acquired by Immediatek, Inc.  Immediatek is currently traded
on the OTC-BB.  From February, 2000 to March, 2007, he held the position as
President/Director of Eaton Laboratories, Inc.  In March, 2007, Eaton
Laboratories was acquired by Hydrogen Hybrid Technologies, Inc, a Canadian-
based firm which is currently traded on OTC-BB under the stock symbol HYHY.
From inception to present, he has held the position as President/ Director of
IVPSA Corporation.  IVPSA Corporation was a subsidiary of Eaton Laboratories.
IVPSA Corporation subsequently acquired EZJR, Inc.


                                      31
<PAGE>


Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), requires our executive officers and directors, and persons
who beneficially own more than ten percent of our common stock, to file
initial reports of ownership and reports of changes in ownership with the
SEC. Executive officers, directors and greater than ten percent beneficial
owners are required by SEC regulations to furnish us with copies of all
Section 16(a) forms they file.  Based upon a review of the copies of such
forms furnished to us and written representations from our executive officers
and directors, we believe that as of the date of this report they were not
current in his 16(a) reports.


Board of Directors

Our board of directors currently consists of one member, Mr. Jesky.  Our
directors serve one-year terms.

Audit Committee
---------------

The company does not presently have an Audit Committee.  The sole member of
the Board sits as the Audit Committee.  No qualified financial expert has
been hired because the company is too small to afford such expense.


Committees and Procedures
-------------------------

     (1)  The registrant has no standing audit, nominating and compensation
          committees of the Board of Directors, or committees performing
          similar functions.  The Board acts itself in lieu of committees due
          to its small size.

     (2)  The view of the board of directors is that it is appropriate for the
          registrant not to have such a committee because its directors
          participate in the consideration of director nominees and the
          board and the company are so small.

     (3)  The members of the Board who acts as nominating committee is
          not independent, pursuant to the definition of independence of a
          national securities exchange registered pursuant to section 6(a)
          of the Act (15 U.S.C. 78f(a).

     (4)  The nominating committee has no policy with regard to the
          consideration of any director candidates recommended by security
          holders, but the committee will consider director candidates
          recommended by security holders.

                                        32
<PAGE>


     (5)  The basis for the view of the board of directors that it is
          appropriate for the registrant not to have such a policy is that
          there is no need to adopt a policy for a small company.

     (6)  The nominating committee will consider candidates recommended by
          security holders, and by security holders in submitting such
          recommendations.

     (7)  There are no specific, minimum qualifications that the nominating
          committee believes must be met by a nominee recommended by security
          holders except to find anyone willing to serve with a clean
          background.

     (8)  The nominating committee's process for identifying and evaluation
          of nominees for director, including nominees recommended by security
          holders, is to find qualified persons willing to serve with a clean
          backgrounds.  There are no differences in the manner in which the
          nominating committee evaluates nominees for director based on
          whether the nominee is recommended by a security holder, or found
          by the board.


Code of Ethics

We have not adopted a Code of Ethics for the Board and any salaried
employees.


Limitation of Liability of Directors
------------------------------------

Pursuant to the Nevada General Corporation Law, our Articles of Incorporation
exclude personal liability for our Directors for monetary damages based upon
any violation of their fiduciary duties as Directors, except as to liability
for any breach of the duty of loyalty, acts or omissions not in good faith or
which involve intentional misconduct or a knowing violation of law, or any
transaction from which a Director receives an improper personal benefit. This
exclusion of liability does not limit any right which a Director may have to
be indemnified and does not affect any Director's liability under federal or
applicable state securities laws.  We have agreed to indemnify our directors
against expenses, judgments, and amounts paid in settlement in connection
with any claim against a Director if he acted in good faith and in a manner
he believed to be in our best interests.


                                        33
<PAGE>


Nevada Anti-Takeover Law and Charter and By-law Provisions
----------------------------------------------------------

The anti-takeover provisions of Sections 78.411 through 78.445 of the Nevada
Corporation Law apply to EZJR.  Section 78.438 of the Nevada law prohibits
the Company from merging with or selling more than 5% of our assets or stock
to any shareholder who owns or owned more than 10% of any stock or any entity
related to a 10% shareholder for three years after the date on which the
shareholder acquired the EZJR shares, unless the transaction is approved by
EZJR's Board of Directors.  The provisions also prohibit the Company from
completing any of the transactions described in the preceding sentence with a
10% shareholder who has held the shares more than three years and its related
entities unless the transaction is approved by our Board of Directors or a
majority of our shares, other than shares owned by that 10% shareholder or
any related entity.  These provisions could delay, defer or prevent a change
in control of EZJR, Inc.


Item 11. Executive Compensation.


The following table sets forth summary compensation information for the
fiscal year ended June 30, 2008 for our Chief Executive Officer, who was
appointed on August 14, 2006.  We did not have any executive officers as of
the year end of June 30, 2008 who received any compensation.

Compensation
------------

As a result of our the Company's current limited available cash, no officer
or director received compensation since August 14, 2006 (inception) of the
company through the fiscal years ending June 30, 2008 and June 30, 2007.  EZJR
has no intention of paying any salaries at this time.  We intend to pay
salaries when cash flow permits.

<TABLE>
<CAPTION>

Summary Compensation Table
--------------------------

                                                             All
                             Fiscal                         Other
                             Year                           Compen-
                             Ending  Salary Bonus  Awards   sation    Total
Name and Principal Position  June 30  ($)    ($)    ($)       ($)      ($)
----------------------------------------------------------------------------
<S>                <C>       <C>     <C>    <C>      <C>     <C>        <C>
T J Jesky          CEO/Dir.  2008    -0-    -0-      -0-     -0-        -0-
                             2007    -0-    -0-      -0-     -0-        -0-

</TABLE>

                                        34
<PAGE>


We do not have any employment agreements with our officers/directors.  We do
not maintain key-man life insurance for any our executive officers/directors.
We do not have any long-term compensation plans or stock option plans.


Stock Option Grants
-------------------

We did not grant any stock options to the executive officers or directors
from inception through fiscal year end June 30, 2008.


Outstanding Equity Awards at Fiscal Year-Ending June 30, 2008
-------------------------------------------------------------

We did not have any outstanding equity awards as of June 30, 2008.

Option Exercises for Fiscal Year-Ending June 30, 2008
-----------------------------------------------------

There were no options exercised by our named executive officer in
fiscal year ending June 30, 2008.

Potential Payments Upon Termination or Change in Control
--------------------------------------------------------

We have not entered into any compensatory plans or arrangements with respect
to our named executive officer, which would in any way result in payments to
such officer because of his resignation, retirement, or other termination of
employment with us or our subsidiaries, or any change in control of, or a
change in his responsibilities following a change in control.

Director Compensation
---------------------

We did not pay our directors any compensation during fiscal years ending
June 30, 2008 or June 30, 2007.









                                      35
<PAGE>


Item 12.  Security Ownership of Certain Beneficial Owners and Management and
Related Stockholder Matters.

The following table presents information, to the best of our knowledge, about
the ownership of our common stock on September 23, 2008 relating to those
persons known to beneficially own more than 5% of our capital stock and by
our named executive officer and sole director. The percentage of beneficial
ownership for the following table is based on 10,873,750 shares of common
stock outstanding.

Beneficial ownership is determined in accordance with the rules of the
Securities and Exchange Commission and does not necessarily indicate
beneficial ownership for any other purpose.  Under these rules, beneficial
ownership includes those shares of common stock over which the stockholder
has sole or shared voting or investment power.  It also includes shares of
common stock that the stockholder has a right to acquire within 60 days after
September 23, 2008 pursuant to options, warrants, conversion privileges or
other right. The percentage ownership of the outstanding common stock,
however, is based on the assumption, expressly required by the rules of the
Securities and Exchange Commission, that only the person or entity whose
ownership is being reported has converted options or warrants into shares of
EZJR's common stock.

<TABLE>
<CAPTION>

                                                     Amount
Title     Name and Address                           of shares      Percent
of        of Beneficial                              held by          of
Class     Owner of Shares         Position           Owner          Class(1)
----------------------------------------------------------------------------
<S>        <C>                    <C>                <C>             <C>
Common     T J Jesky (2)          Pres./Director     4,000,000       36.7%
Common     Mark DeStefano (3)     Shareholder        3,500,000       32.2%
---------------------------------------------------------------------------
All Executive Officers, Directors
as a Group  (1 person)                               4,000,000       36.7%

(1)  The percentages listed in the Percent of Class column are based upon
     10,873,750 issued and outstanding shares of Common Stock.
(2)  T J Jesky, 2235 E. Flamingo, Suite 114, Las Vegas, NV 89119.
(3)  Mark DeStefano, 500 N. Rainbow, Suite 300, Las Vegas, NV  89107.

</TABLE>

We are not aware of any arrangements that may result in "changes in control"
as that term is defined by the provisions of Item 403(c) of Regulation S-B.



                                        36
<PAGE>


We believe that all persons named have full voting and investment power with
respect to the shares indicated, unless otherwise noted in the table. Under
the rules of the Securities and Exchange Commission, a person (or group of
persons) is deemed to be a "beneficial owner" of a security if he or she,
directly or indirectly, has or shares the power to vote or to direct the
voting of such security, or the power to dispose of or to direct the
disposition of such security. Accordingly, more than one person may be deemed
to be a beneficial owner of the same security. A person is also deemed to be
a beneficial owner of any security, which that person has the right to
acquire within 60 days, such as options or warrants to purchase our common
stock.


Item 13. Certain Relationships and Related Transactions, and Director
Independence.

The company's sole officer/director has contributed office space for our use.
There is no charge to us for the space.  Our officer will not seek
reimbursement for past office expenses.

Through a Board Resolution, the Company hired the professional services of
Moore & Associates, Chartered, Certified Public Accountants, to perform
audited financials for the Company.  Moore & Associates, Chartered own no
stock in the Company.  The company has no formal contracts with its
accountants, they are paid on a fee for service basis.

Other than as set forth above, there are no transactions since our inception,
or proposed transactions, to which we were or are to be a party, in which any
of the following persons had or is to have a direct or indirect material
interest:

a) Any director or executive officer of the small business issuer;

b) Any majority security holder; and

c) Any member of the immediate family (including spouse, parents, children,
   siblings, and in-laws) of any of the persons in the above.


                                        37
<PAGE>


Item 14. Principal Accountant Fees and Services.

Moore & Associates, Chartered served as our principal independent public
accountants for fiscal years ending June 30, 2008 and June 30, 2007.
Aggregate fees billed to us for the years ended June 30, 2008 and 2007 by
Moore & Associates were as follows:

<TABLE>
<CAPTION>

                                                         For the Years Ended
                                                               June 30,
                                                         -------------------
                                                            2008      2007
                                                         -------------------
<S>                                                        <C>        <C>
 (1) Audit Fees(1)                                         $5,000     $4,000
(2) Audit-Related Fees                                       -0-        -0-
(3) Tax Fees                                                 -0-        -0-
(4) All Other Fees                                           -0-        -0-

Total fees paid or accrued to our principal accountant

</TABLE>

(1)  Audit Fees include fees billed and expected to be billed for services
performed to comply with Generally Accepted Auditing Standards (GAAS),
including the recurring audit of the Company's financial statements for such
period included in this Annual Report on Form 10-K and for the reviews of the
quarterly financial statements included in the Quarterly Reports on Form 10-
QSB filed with the Securities and Exchange Commission.


Audit Committee Policies and Procedures
---------------------------------------

We do not have an audit committee; therefore our sole director pre-approves
all services to be provided to us by our independent auditor.  This process
involves obtaining (i) a written description of the proposed services, (ii)
the confirmation of our Principal Accounting Officer that the services are
compatible with maintaining specific principles relating to independence, and
(iii) confirmation from our securities counsel that the services are not
among those that our independent auditors have been prohibited from
performing under SEC rules.  Our sole director then makes a determination to
approve or disapprove the engagement of Moore & Associates for the proposed
services.  In fiscal 2007, all fees paid to Moore & Associates were
unanimously pre-approved in accordance with this policy.

Less than 50 percent of hours expended on the principal accountant's
engagement to audit the registrant's financial statements for the most recent
fiscal year were attributed to work performed by persons other than the
principal accountant's full-time, permanent employees.

                                        38
<PAGE>


                                     PART IV

Item 15. Exhibits, Financial Statement Schedules.

The following information required under this item is filed as part of
this report:


(a) 1. Financial Statements

                                                                     Page
                                                                     ----
Management's Report on Internal Control Over Financial Reporting       28
Report of Independent Registered Public Accounting Firm               F-1
Balance Sheets                                                        F-2
Statements of Operations                                              F-3
Statements of Stockholders' Equity                                    F-4
Statements of Cash Flows                                              F-5


(b) 2. Financial Statement Schedules

None.
















                                        39
<PAGE>


(c) 3. Exhibit Index

                                                 Incorporated by reference
                                                 -------------------------

                                        Filed          Period           Filing
Exhibit       Exhibit Description     herewith  Form   ending  Exhibit   date
------------------------------------------------------------------------------
2.1        Acquisition and Plan of              8-K              2.1   7/28/08
           Merger between EZJR, Inc.
           and IVPSA Corporation
           dated July 25, 2008.
------------------------------------------------------------------------------
3.1        Articles of Incorporation,    X
           as currently in effect
------------------------------------------------------------------------------
3.2        Bylaws                        X
           as currently in effect
------------------------------------------------------------------------------
3.3        Articles of Merger            X
           between EZJR, Inc. and
           IVPSA Corporation
------------------------------------------------------------------------------
10.1       Exclusive Option Agreement           8-K             10.1   7/28/08
           between IVPSA Corporation
           and the Cleveland Clinic,
           dated March 15, 2007
------------------------------------------------------------------------------
10.2       Extension of Exclusive               8-K             10.2   7/28/08
           Option Agreement between
           IVPSA Corporation and
           the Cleveland Clinic,
           dated April 14, 2008.
------------------------------------------------------------------------------
23.1       Consent Letter from Moore     X
           and Associates Chartered
------------------------------------------------------------------------------
31.1       Certification of President    X
           and Principal Financial
           Officer, pursuant to Section
           302 of the Sarbanes-Oxley
           Act
------------------------------------------------------------------------------
31.2       Certification of President    X
           and Principal Financial
           Officer, pursuant to Section
           906 of the Sarbanes-Oxley
           Act
------------------------------------------------------------------------------


                                     40
<PAGE>


                                   SIGNATURES

In accordance with Section 13 or 15(d) of the Securities Exchange Act, the
registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.


EZJR, Inc.

By: /s/ T J Jesky
    -------------
        T J Jesky
        President

Date:  September 24, 2008
       ------------------

Pursuant to the requirements of the Securities Exchange Act of 1934, the
following persons on behalf of the Registrant and in the capacities and on
the dates indicated have signed this report below.

Name


By: /s/ T J Jesky
    -------------
        T J Jesky
        President, Secretary,
        Treasurer and Director
        (Principal Executive,
        Principal Financial and
        Principal Accounting Officer)


Date:  September 24, 2008
       ------------------


                                      41
<PAGE>